LTFS
SMMT icon

Ladenburg Thalmann Financial Services’s Summit Therapeutics SMMT Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-100
Closed -$1K – 4945
2016
Q3 		$1K Hold
100
– – ﹤0.01% 4650
2016
Q2 		$1K Hold
100
– – ﹤0.01% 4607
2016
Q1 		$1K Hold
100
– – ﹤0.01% 4556
2015
Q4 		$1K Buy
+100
New +$1.04K ﹤0.01% 4541

Other funds holding SMMT

LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ladenburg Thalmann Financial Services's SMMT Position: Q4 2016 in Review

Ladenburg Thalmann Financial Services sold out of Summit Therapeutics (SMMT) in Q4 2016, closing a stake of 100 shares — an estimated $1K sold.

Ladenburg Thalmann Financial Services first reported a position in SMMT in Q4 2015 and held it in 4 quarters. The position peaked at $1K in Q3 2016. 11 funds tracked by Wall St. Rank hold SMMT as of Q4 2016.

  • Ladenburg Thalmann Financial Services reported no remaining Summit Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 100 Summit Therapeutics shares in Q4 2016, an estimated $1K.
  • Ladenburg Thalmann Financial Services first reported a position in Summit Therapeutics in Q4 2015 and held it in 4 quarters.
  • Ladenburg Thalmann Financial Services's Summit Therapeutics position peaked at $1K in Q3 2016.
  • 11 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2016.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2016, filed 14 Feb 2017.